Clinical Scorecard: Exploring Trends in HPV-Associated Cancers in Norway: A Focus Beyond Women's Health

At a Glance

Key Highlights

• Incidence of HPV-attributable cancers not prevented by screening is rising, surpassing cervical cancer incidence and projected to continue increasing until 2038.
• Cervical squamous cell carcinoma incidence in women decreased by 6% annually from 2018 to 2023 following implementation of HPV testing as primary screening.
• HPV vaccination introduced nationally for girls in 2009 and boys in 2018, with no catch-up program for men, influencing future cancer incidence trends.

Guideline-Based Recommendations

Diagnosis

• Use of HPV testing as primary cervical cancer screening method to increase detection of precancerous lesions.
• Cancer registry data collection with tumor topography and morphology to monitor HPV-attributable cancer incidence.

Management

• Organized cervical cancer screening programs to detect and treat precancers before progression.
• Implementation of prophylactic HPV vaccination in childhood immunization programs for both girls and boys.

Monitoring & Follow-up

• Continuous population-based surveillance of HPV-attributable cancer incidence using high-quality cancer registry data.
• Forecasting incidence trends to inform preventive strategies and resource allocation.

Risks

• Rising incidence of HPV-attributable cancers at noncervical sites, especially oropharyngeal squamous cell carcinoma in men.
• Lack of early detection programs for noncervical HPV-related cancers.
• Absence of catch-up HPV vaccination programs for men may limit prevention in older cohorts.

Patient & Prescribing Data

Norwegian population including vaccinated girls (since 2009) and boys (since 2018), and unvaccinated older cohorts

HPV vaccination coverage is expected to reduce HPV-attributable cancer incidence as vaccinated cohorts age; cervical screening improvements have already reduced cervical SCC incidence.

Clinical Best Practices

• Maintain and enhance organized cervical cancer screening with HPV testing as primary modality.
• Promote and sustain high HPV vaccination coverage in both sexes starting in childhood.
• Develop preventive strategies addressing rising HPV-attributable cancers beyond cervical cancer, including awareness and research on noncervical sites.
• Utilize high-quality cancer registry data for ongoing monitoring and forecasting of HPV-related cancer trends.

References

• Cancer Registry of Norway
• World Health Organization HPV Classification 2020
• Norwegian National HPV Vaccination Program